Sigma Foods SAB de CV (ALFFF) reports robust revenue and EBITDA growth, driven by strong regional performances and strategic expansions, despite rising financial costs.

The company operates a single plant in Georgia and generated around $50m in revenue in 2025, Sigma said.

The fair value price target for Sigma Foods.de has been updated to MX$20.90, compared with the previous MX$20.54, based on refreshed model assumptions. Analysts who are constructive on the name broadly see this revised level as consistent with current expectations, while more cautious voices question how much room it leaves for execution risks and sector headwinds. As you read on, you will see how these differing views, plus the recent product news, shape the evolving Sigma Foods.de story and...

The latest update edges Sigma Foods’ fair value estimate from MX$20.29 to MX$20.54 per share, reflecting refined inputs in the existing model rather than a wholesale reset of expectations. Recent neutral coverage from JPMorgan and other analysts broadly treats this MX$20.54 level as in line with the current story, with both strengths and pressure points in view. Read on to see what is shaping that narrative and how you can track future shifts in the outlook for Sigma Foods. de. Analyst Price...

The fair value price target for Sigma Foods.de holds at MX$20.29, keeping the central valuation marker steady for now. JPMorgan's neutral initiation aligns with this unchanged target and indicates that analysts currently see the shares as broadly in line with their assumptions rather than mispriced. As you read on, you will see what is shaping this narrative and what to watch as new information comes in. Stay updated as the Fair Value for Sigma Foods. de shifts by adding it to your watchlist...

The cider brand has added a high-contrast NaviLens QR code to its cans.

BioReference health, JPMorgan Chase and an Italian fashion retailer are making the job cuts amid market uncertainty

Novartis will acquire Tourmaline Bio for $48 per share, valuing the New York-based biopharmaceutical company at $1.4 billion on a fully diluted basis, the Swiss pharma giant said on Tuesday. Tourmaline is focused on developing pacibekitug, a promising targeted therapy with the potential to reduce systemic inflammation, as a treatment option for atherosclerotic cardiovascular disease, Novartis said in a statement. With the deal, Novartis will acquire a Phase III-ready asset that will complement its existing cardiovascular disease portfolio, it said.